Maintenance Therapy: Lenalidomide Following Bendamustine and Rituximab Induction Therapy for Chronic Lymphocytic Leukemia

This study has been terminated.
(This study was unsuccessful in enrolling the target number of subjects during the funding period.)
Celgene Corporation
Information provided by (Responsible Party):
Yale University Identifier:
First received: October 28, 2011
Last updated: June 12, 2014
Last verified: June 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Study Completion Date: November 2013
  Primary Completion Date: November 2013 (Final data collection date for primary outcome measure)